Natera to showcase ultrasensitive MRD test at ESMO, showing treatment de‑escalation in colon cancer trial
Natera announced that it will present 20 abstracts at the 2026 European Society for Medical Oncology Congress, highlighting its Signatera Genome test with phased and structural variants that can detect circulating tumor DNA well below 1 part per 10 million. In the phase‑III SAGITTARIUS colon‑cancer trial, the test prompted a change in the pre‑planned adjuvant therapy for one in three patients, and 87% of those changes were treatment de‑escalations based on MRD negativity. The company’s chief medical officer emphasized the unprecedented analytical limit of detection (LOD95) of 1 part per million.
Why it matters
The market reacted positively, with Natera shares rising 2.4% after the announcement. Clinically, the data suggest the test can safely reduce overtreatment for a substantial share of colon‑cancer patients, potentially lowering therapy costs and side‑effects.
Key facts
- 1Natera will present 20 abstracts, including 4 rapid oral presentations, at the ESMO Annual Congress on October 23–26, 2026. stocktitan.net
- 2The Signatera Genome test achieved an analytical limit of detection (LOD95) below 1 part per million and detection significantly below 1 part per 10 million. stocktitan.net
- 3In the SAGITTARIUS phase‑III colon‑cancer trial, Signatera results changed the pre‑planned adjuvant treatment for one in three patients. stocktitan.net
- 4Of the treatment changes in SAGITTARIUS, 87% were de‑escalations based on MRD negativity. stocktitan.net
- 5Shares of Natera jumped 2.4% in the afternoon session after the announcement. financialcontent.com
- 6The stock closed at $401.75, up 2.1% from the previous close. financialcontent.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.